iA Global Asset Management Inc. Increases Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

iA Global Asset Management Inc. grew its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 9.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 208,709 shares of the company’s stock after buying an additional 18,100 shares during the quarter. iA Global Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $4,216,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. AQR Capital Management LLC lifted its stake in Teva Pharmaceutical Industries by 24.6% in the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after acquiring an additional 4,732 shares during the period. Focus Partners Wealth increased its position in Teva Pharmaceutical Industries by 4.5% during the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after purchasing an additional 1,739 shares during the period. GAMMA Investing LLC raised its holdings in Teva Pharmaceutical Industries by 65.9% in the 2nd quarter. GAMMA Investing LLC now owns 7,282 shares of the company’s stock worth $122,000 after purchasing an additional 2,892 shares in the last quarter. Fifth Third Bancorp lifted its position in shares of Teva Pharmaceutical Industries by 49.2% in the 2nd quarter. Fifth Third Bancorp now owns 32,805 shares of the company’s stock worth $550,000 after purchasing an additional 10,820 shares during the period. Finally, Hartford Investment Management Co. boosted its stake in shares of Teva Pharmaceutical Industries by 30.9% during the 2nd quarter. Hartford Investment Management Co. now owns 13,796 shares of the company’s stock valued at $231,000 after purchasing an additional 3,257 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

TEVA has been the topic of several research analyst reports. Piper Sandler boosted their price target on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, December 22nd. Barclays assumed coverage on Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 price objective on the stock. Bank of America increased their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. The Goldman Sachs Group raised their target price on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Finally, Scotiabank initiated coverage on Teva Pharmaceutical Industries in a research report on Friday, December 5th. They set a “sector outperform” rating and a $35.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $33.67.

Insider Buying and Selling

In other news, CAO Amir Weiss sold 12,300 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the sale, the chief accounting officer directly owned 5,650 shares of the company’s stock, valued at approximately $170,630. This represents a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Mark Sabag sold 216,892 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the transaction, the insider directly owned 52,828 shares of the company’s stock, valued at approximately $1,517,748.44. This represents a 80.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 622,060 shares of company stock valued at $17,076,965. 0.49% of the stock is owned by insiders.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $31.83 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The stock has a market cap of $36.51 billion, a P/E ratio of 53.05, a P/E/G ratio of 1.81 and a beta of 0.66. The business’s 50 day moving average price is $29.64 and its 200-day moving average price is $22.58. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $33.42.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.